Testicular Cancer Conference Boston 2025
THANK YOU TO EVERYONE WHO SUPPORTED AND ATTENDED THE TESTICULAR CANCER CONFERENCE 2025 IN BOSTON, HELD AT HARVARD MEDICAL SCHOOL!
Our 10th Testicular Cancer Conference was an incredible success, and our largest yet, thanks to the passionate support of this amazing community. We are especially grateful to our title sponsor, Fennec Pharmaceuticals, as well as Mass General Brigham, Dana-Farber Cancer Institute, and Harvard Medical School for helping make this event possible.
Presented by fennec pharmaceuticals
September 25-26, 2025
Bringing Survivors, Patients, Caregivers, and Medical Experts Together
We are focused on bringing an international group of TC patients, survivors, and their loved ones together to address the physical and emotional toll of being diagnosed and treated for testicular cancer. We discuss life with and after cancer, and lifestyle changes that can help the healing process. We invite a panel of medical experts to provide pertinent information for patients currently fighting and resources for long-term survivorship. TCAF provides attendees with information and resources to advocate within their community about the importance of early detection.
SCHEDULE OF EVENTS
Friday, September 26:
CONFERENCE DAY
8:00 AM - 5:00 PM
Held at the Joseph B. Martin Conference Center at Harvard Medical School
Address: 77 Avenue Louis Pasteur, Boston, MA 02115
Start your day with complimentary coffee and a continental breakfast available during Registration.
Registration: 8:00 – 8:40 AM
Conference Welcome: 8:45 AM
Catered Lunch: 12:00 – 1:00 PM
Welcome Back: 1:05 PM
15 Minute Break: 2:45 – 3:00 PM
Breakout Sessions: 3:00 – 5:00 PM
Thursday, September 25:
DINNER SOCIAL
6:00 - 9:00 PM
Mt. Auburn Ballroom
Hyatt Regency Boston/Cambridge
Address: 575 Memorial Drive, Cambridge, MA 02139
Join us for a relaxed evening of great food, drinks, and connection! Mingle with fellow attendees, survivors, families, and physicians as we come together to launch an inspiring conference.
Business casual attire recommended.
Refundable Registration Policy: To ensure commitment and accurate planning, a small registration fee was required to reserve a spot at the conference. However, this fee will be fully refunded to those who attended the conference.
The refund process will take 7-10 business days.
OUR EMCEE FOR TCC BOSTON 2025…
BJ Lange
Survivor & TCAF Board Member
Retired USAF Medic, Hollywood Actor
BJ Lange is an Actor, 2X Testicular Cancer Survivor, & TCAF Board Member. Seen on MTV, General Hospital and The Rookie, BJ is a graduate of The Second City, where he is now an instructor. He is also an alumnus of iO West and UCBTLA, and a member of Warriors for Peace Theatre – a veteran Shakespeare Company. He’s a proud member of SAG-AFTRA and Actor's Equity. Off the screen and stage, BJ uses his experience as a retired USAF medic as a clinical instructor at UCLA's Center for Prehospital Care at the David Geffen School of Medicine Department of Emergency Medicine. Connect and watch BJ follow his dreams at BJLange.com
Lead Chair for this year’s conference:
Dr. Timothy Clinton - Mass General Brigham & Dana-Farber cancer Institute
Dr. Clinton’s clinical interests are in the treatment of all genitourinary malignancies with a focus on urothelial carcinoma and testicular cancer utilizing both open and robotic approaches. His research interests are defining the genomic determinants of urothelial carcinoma and germ cell tumors.
Presentation & Breakout Topics:
Honorary Speaker - Darren Feldman, MD, Memorial Sloan Kettering Cancer Center - Genitourinary Medical Oncologist
Quality of Life - Richard Matulewicz, MD, MSCI, MS, Memorial Sloan Kettering Cancer Center - Surgical Urologist
Ototoxicity - Pierre Sayad, PhD, MS, Fennec Pharmaceuticals - Molecular Physiologist & Chief Medical Officer
Adolescent & Young Adult Center at DFCI & MaGIC - Lindsay Frazier, MD, Dana-Farber Cancer Institute & Boston Children’s Hospital - Attending Physician, Pediatric Hematology/Oncology
Survivorship for Adults at DFCI - Stephanie Berg, DO, Dana-Farber Cancer Institute - Genitourinary Medical Oncologist
Survivor Testimonial - Anthony Spina - Testicular Cancer Survivor, F.N.P.
Mental Health - Lydia Chevalier, PhD, Dana-Farber Cancer Institute - Clinical Psychologist
Insomnia & Cancer- Dr. Christopher Recklitis, Dana-Farber Cancer Institute - Clinical Psychologist
Men’s Health, Fertility & Testosterone - Martin Kathrins, MD, Mass General Brigham - Chief of Benign Urology & Director of Men’s Health Center
A Personalized Approach to Cancer Management Using Circulating Tumor DNA (ctDNA) - Keith Hanigan, Natera Representative
Inspirational Speaker - T. Clark Gamblin, MD, MS, MBA, Testicular Cancer Survivor and Inaugural Chief of Surgical Oncology at Huntsman Cancer Institute & University of Utah Health
Special Guest - Jesse Solomon, Summer House Bravo TV - Two-time Testicular Cancer Survivor and Reality TV Personality
Expert Q&A Panel - A dynamic, large-format session where our specialists take the stage to answer questions directly from the audience, offering insights, guidance, and expert opinions in real time
Breakout Sessions
Docs Q&A Session - Small-group breakout sessions for attendees to engage in more personal conversations with physicians
Survivors Unite - Lead by Testicular Cancer Survivors LTC Sean Kern, MD & Emcee BJ Lange
Caregivers Unite - Lead by Lead Chair Timothy Clinton, MD
GUEST Speakers
Timothy Clinton, MD
Lead Chair
Mass General Brigham & Dana-Farber Cancer Institute
Dr. Clinton received a Bachelor of Arts in cell and molecular biology and music from Tulane University and his medical degree from the University of Texas Health Science Center San Antonio. He also holds a Master of Public Health from the University of Texas School of Public Health. Dr. Clinton completed a residency in Urology at the University of Texas Southwestern Medical Center in Dallas, TX. Following residency, he was a Urologic Oncology fellow at Memorial Sloan Kettering Cancer Center.
Before coming to the Brigham, Dr. Clinton was a clinical instructor of urologic oncology in the Department of Surgery at Memorial Sloan Kettering Cancer Center. He is now an Assistant Professor of Surgery at Harvard Medical School, Associate Surgeon at Mass General Brigham and a Surgical Oncologist at Dana-Farber Cancer Institute.
Dr. Clinton’s clinical interests are in the treatment of all genitourinary malignancies with a focus on urothelial carcinoma and testicular cancer utilizing both open and robotic approaches. His research interests are defining the genomic determinants of urothelial carcinoma and germ cell tumors.
Darren Feldman, MD
Honorary Speaker
Memorial Sloan Kettering Cancer Center
Dr. Feldman is an Associate Attending Physician on the Genitourinary Oncology Service and Bone Marrow Transplant (BMT) Service within the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC) and Associate Professor of Medicine at Weill Medical College of Cornell University, both in New York City, NY.
He completed his Internal Medicine residency at New York University before serving as chief resident for the Department of Medicine at MSKCC, where he went on to complete fellowship in medical oncology and hematology.
Dr. Feldman’s research focuses on understanding the biology and improving the treatment for patients with germ cell tumors (GCT) and kidney tumors. Additionally, he is interested in the mechanism and management of late toxicities resulting from GCT treatment, particularly effects on the cardiovascular system. He also served as the Chair of Quality Assurance for the Department of Medicine at MSKCC from 2018 to 2024.
Dr. Feldman is the recipient of several awards including the John Mendelsohn Teaching Award and the Paul Sherlock Housestaff Teaching Award for the Department of Medicine at MSKCC and has been recognized in New York Magazine’s Top Doctors in New York City. Dr. Feldman has published over 200 peer-reviewed manuscripts on urologic malignancies and authored review chapters in several prominent textbooks.
Richard Matulewicz, MD, MSCI, MS
Quality of Life
Memorial Sloan Kettering Cancer Center
Dr. Richard Matulewicz is an attending surgeon in the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSK) and holds an Assistant Professor academic appointment at Weill Cornell Medical College. He completed medical school at Tufts University with Alpha Omega Alpha honors which was followed by urology residency at Northwestern University Feinberg School of Medicine in Chicago. After that, he completed a clinical fellowship in urologic oncology at MSK and a research fellowship at NYU in population health and clinical investigation. His clinical practice focuses on the surgical management of testicular cancer. He is also a National Cancer Institute (NCI) grant funded health services researcher and implementation scientist. His research program works to promote survivorship for patients with testicular cancer and other genitourinary malignancies with a focus on health-related quality of life, smoking cessation, and implementation of novel biomarkers.
Twitter/X @RichMatulewicz
Pierre Sayad, PhD, MS
Ototoxicity
Fennec Pharmaceuticals
Dr. Pierre Sayad is a molecular physiologist and seasoned biotech executive with over 20 years of experience in oncology and neuroscience. He earned his doctorate and dual master’s degrees from the School of Medicine at Loma Linda University and completed his executive business training at Harvard Business School. Dr. Sayad has led the development and launch of eight novel therapies across 17 indications. He’s known for building high-performing, cross-functional teams that unite science, medicine, and strategy around a shared mission. A former executive leader of the International Myeloma Foundation, Dr. Sayad is deeply committed to patient-centered innovation. His work focuses on improving quality of life for patients and ensuring their experiences shape the future of cancer care.
Anthony Spina, Testicular Cancer Survivor & FNP
Testicular Cancer Awareness Foundation Volunteer
Pedmark Testimonial
Anthony Spina is a testicular cancer survivor who was successfully treated with Pedmark - a therapy developed by Fennec Pharmaceuticals that helps reduce or prevent cisplatin-induced hearing loss during his cancer treatment.
Lindsay Frazier, MD, ScM
Adolescent & Young Adult Center at DFCI and MaGIC
Dana-Farber Cancer Institute, Harvard Medical School, Harvard Chan School of Public Health
Dr. A. Lindsay Frazier is a Professor of Pediatrics at Harvard Medical School and an Institute Physician at the Dana-Farber Cancer Institute. Dr. Frazier is also a Professor of Epidemiology at the Harvard Chan School of Public Health. Dr. Frazier leads the Malignant Germ Cell International Consortium which is conducting research across the spectrum of cancer research from basic biology to clinical trials to survivorship. MaGIC now consists of 140 GCT experts from 17 countries. Dr. Frazier also co-leads the Center for Adolescent and Young Adult Oncology at Dana-Farber Cancer Institute. Dr. Frazier also has an interest in mentorship and mentorship training and currently serves as Principal Facilitator for the Center for the Improvement in the Mentored Experience in Research (CIMER).
Stephanie Berg, DO
Survivorship for Adults at DFCI
Dana-Farber Cancer Institute
Dr. Stephanie Berg is a medical oncologist for the Lank Center of Genitourinary Oncology. She completed her medical education at the Lake Erie College of Osteopathic Medicine. Her post-graduate training in Internal Medicine was completed at the University of Illinois-Chicago where she served as Chief Resident and hematology-oncology fellowship at Loyola University Medical Center where she served as Chief Fellow. She was an Assistant Professor of Medicine at Loyola University Chicago in the Department of Medicine and Cancer Biology from 2018-2022. Prior to her arrival at Dana-Farber Cancer Institute, she was the junior faculty lead of the Genitourinary Medical Oncology Program at the Cardinal Bernardin Cancer Center of Loyola University Chicago. She was also the research head of Renal Cell Cancer clinical trials and served as the principal investigator on several cooperative group and industry sponsored trials. Her aim is to be at the forefront of translating basic science research to better understand the pathogenesis of cancer development, participate in novel gene discovery and identify potential molecular therapeutic targets for future genitourinary cancer treatment. She has a special interest in older adult oncology and novel immunotherapy drug development.
Twiiter/X @bergsa83
Lydia Chevalier, PhD
Mental Health
Dana-Farber Cancer Institute
Lydia Chevalier, Ph.D. is a licensed clinical psychologist at Dana-Farber Cancer Institute and Instructor in Psychiatry at Harvard Medical School. She earned her Doctorate in Clinical Psychology from Boston University and completed her predoctoral residency at the University of Washington in the Behavioral Medicine track. Dr. Chevalier then completed a research fellowship at Dana-Farber Cancer Institute in pediatric cancer survivorship supported by the Swim Across American Foundation. During her fellowship, Dr. Chevalier conducted research evaluating psychosocial late effects of cancer treatment (e.g., sexual dysfunction, insomnia, anxiety) and received the Helen Gurley Brown Presidential Initiative Award. This award allowed Dr. Chevalier to transition to faculty at Dana-Farber Cancer Institute, where she continues to conduct survivorship research with a focus on sexual health, dating, and body image in young adult cancer survivors. Clinically, she provides evidence-based treatment for cancer survivors of all ages experiencing sexual health concerns, anxiety, depression, and other behavioral health conditions.
Christopher Recklitis, PhD, MPH
Insomnia & Cancer
Dana-Farber Cancer Institute
Christopher J. Recklitis, Ph.D., MPH is Director of Research and Support Services for the Perini Family Survivors Center at Dana-Farber, and Associate Professor of Pediatrics at Harvard Medical School. He completed doctoral degree in clinical psychology at Boston University, and his Masters in Public Health at the Harvard School of Public Health. Dr. Recklitis's research is focused on understanding the psychological late-effects of cancer, the development of effective screening measures for detecting distress, and the best methods for encouraging health protective behaviors in cancer survivors. He is the Principal Investigator of Project REACH, a longitudinal study of health outcomes in several hundred locally treated cancer survivors. His work has been supported by grants from the National Cancer Institute, Lance Armstrong Foundation, American Foundation for the Prevention of Suicide, and the Childhood Brain Tumor Foundation.
Martin Kathrins, MD
Men’s Health, Fertility & Testosterone
Mass General Brigham
Dr. Martin Kathrins is an associate surgeon at Brigham and Women’s Hospital and assistant professor of surgery at Harvard Medical School. He is chief of the division of benign urology at Mass General Brigham. Dr. Kathrins received his undergraduate degree from the University of Pennsylvania. He received his medical degree from Columbia University College of Physicians and Surgeons and completed his urology residency at the University of Pennsylvania. He subsequently completed a fellowship in male infertility, andrology and microsurgery at the University of Illinois at Chicago. He is board certified in urology. Dr. Kathrins’ clinical interests include male infertility, hypogonadism, sexual dysfunction and voiding dysfunction.
Twitter/X @KathrinsMD
Jesse Solomon
Guest Speaker
Two-time Testicular Cancer Survivor & Reality TV Personality
Summer House | Bravo TV
Jesse Solomon is an entrepreneur and TV personality on Bravo's Summer House who became a two-time testicular cancer survivor after a diagnosis at 24. He uses his platform to raise awareness for testicular cancer, encouraging men to perform regular self-exams and see a doctor about any potential concerns to ensure early detection and successful treatment. His journey was documented on Summer House, including a scary moment during his five-year checkup.
Bravo reality star Jesse Solomon, 31, says testicular cancer was “one of the better things that's ever happened to me.”
T. Clark Gamblin, MD
Inspirational Speaker
Huntsman Cancer Institute & University of Utah Health
T. Clark Gamblin, MD, MS, MBA is an internationally known hepatobiliary surgeon with a clinical and research focus on cancers of the liver and bile ducts. As a testicular cancer survivor, he completed the epic World Marathon Challenge in January and February of this year, inspiring others and raising funds for the Testicular Cancer Awareness Foundation by running 7 marathons in 7 days across 7 continents.
thank you to all our sponsors:
Thank you to our title sponsor:
Fennec Pharmaceuticals is a biotechnology company dedicated to improving the lives of adolescent and young adult testicular cancer patients by helping reduce the risk of treatment-related hearing loss.
Thank you to our diamond sponsor:
Natera™ is a global leader in cell-free DNA testing, providing personalized molecular residual disease (MRD) testing to help monitor for cancer recurrence and treatment response. Our oncology solutions are designed to empower patients and their care teams with timely, actionable information to support confident decision-making.
Thank you to our GOLD sponsor:
Mass General Brigham is a leading integrated academic health system, known for its world-class patient care, cutting-edge research, and commitment to medical education.
Thank you to our silver sponsor:
Michael and Elizabeth Thompson honoring Thomas Edwards, III, MD; Jason Burnette, MD, PhD; Josh Simmons, MD, FACP and the Archbold Medical Center team where their son, Will Thompson has received and continues to receive exceptional care.
Thank you to our bronze sponsors:
Discover Odd Balls Funguy: organic energy balls infused with lion’s mane and cordyceps mushrooms, designed for thrivers who are determined to boost their performance and live with purpose. Founded by a Testicular Cancer survivor, they’re not just about fueling your journeys; they’re committed to raising awareness about the ‘odd’ balls, bumps, or lumps—that could be early indicators of something more serious. And with their One Ball Initiative, they give back to nonprofits focused on supporting young adults impacted by cancer. So, take a bite, step into the unknown and thrive with us!
Flagstone Foods (“Flagstone”), one of the largest manufacturers and distributors of private label snack nuts and trail mixes in North America, has acquired Emerald Nuts. Their snacks not only taste great, but help you feel good because they are curated with the finest ingredients from around the world